Summit Therapeutics is trading at $15.09, up 4.07%, after partner Akeso reported positive Phase III overall-survival results for ivonescimab plus chemotherapy in advanced biliary tract cancer.
- Presented at ESMO 2026, the trial met its primary endpoint, with median overall survival of 14.9 months versus 12.1 months with the comparator regimen.
- Citizens reaffirmed its Market Outperform rating and $40 price target, citing the trial data.